2019-05-11 10:28:00 Sat ET
technology antitrust competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
The Trump administration still expects to reach a Sino-U.S. trade agreement with a better mechanism for intellectual property protection and enforcement. President Trump emphasizes that there is no need for America to rush to reach a major trade deal with China. Also, there is no need for stock market investors to overreact to the recent Sino-U.S. trade war headlines. The Trump tariff hikes represent punitive penalties on the Chinese attempt to backtrack on prior mutual trade commitments. In response to the Trump tariffs, the Chinese Xi administration promises retaliation with necessary countermeasures.
As Reuters reports in recent times, China retracts key trade elements across all 7 chapters of the 150-page draft agreement and then rolls back promises to change Chinese rules to allay American concerns with respect to intellectual property theft, arbitrary tech transfer, and currency manipulation etc.
The Chinese Xi administration cannot yield to U.S. maximum pressure on matters of principle. As the key Chinese trade reps suggest, the bilateral trade procurement figures should be realistic, and both sides should balance the substantive text of a major trade deal. Furthermore, the Chinese trade negotiators emphasize that this delicate balance should uphold the sovereignty and dignity of the country.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2025-06-21 10:25:00 Saturday ET

Former New York Times science author and Harvard psychologist Daniel Goleman explains why emotional intelligence can serve as a more important critical succ
2026-10-31 12:38:00 Saturday ET

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan. We discuss, desc
2019-05-01 09:27:00 Wednesday ET

Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license with royalty payments to the microchip maker
2022-03-25 09:34:00 Friday ET

Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2016-11-08 00:00:00 Tuesday ET

Donald Trump defies the odds to become the new U.S. president. He wants to make America great again. He seeks to repeal Obamacare. He has zero tole